Expression of RANK-ligand in prostate cancer cell lines.

Abstract

The molecular mediators of bone remodelling, receptor activator of nuclear factor-kappaB ligand (RANKL), receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerine (OPG), are believed to be involved in the cellular mechanisms by which tumours metastasize to bone. RANKL is a potent stimulator of osteoclastic bone resorption and is expressed in a variety of tumour cells. We have investigated if the membrane bound form of RANKL is expressed in prostate cancer cell lines, and whether this expression might be regulated by the presence of human osteoblasts. Three prostate cancer cell lines were co-cultured with human osteoblast-like cells (hOB) and RANKL expression on cell surface was measured by FACS. We found basal expression of RANKL on the cell surface, and in co-culture with hOBs the number of cells expressing RANKL was increased between 2.5 and 4 times. These data suggest a signalling mechanism between bone cells and prostate cancer cells that might increase bone resorption and thereby promote bone metastases.

• Authors: Hendrik Penno, Olle Nilsson, Helena Brändström, Ola Winqvist, Osten Ljunggren
• Journal: Scandinavian journal of clinical and laboratory investigation (Scand J Clin Lab Invest) Vol. 69 Issue 1 Pg. 151-5 ( 2009) ISSN: 1502-7686 [Electronic] England
• PMID: 19058084 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• CD3 Complex
• RANK Ligand
• RNA, Messenger

Topics

• CD3 Complex (metabolism)
• Cell Line, Tumor
• Coculture Techniques
• Gene Expression Regulation, Neoplastic
• Humans
• Male
• Osteoblasts (metabolism)
• Prostatic Neoplasms (genetics)
• RANK Ligand (genetics, metabolism)
• RNA, Messenger (genetics, metabolism)
• Reverse Transcriptase Polymerase Chain Reaction
• T-Lymphocytes (metabolism)